RESUMO: “Efeitos de seco-esteróides purificados de Physalis angulata L., Solanaceae na viabilidade de Leishmania sp.”. Physalis angulata L., Solanaceae, é uma erva anual utilizada na medicina popular em muitos países tropicais e subtropicais. Apesar dos extratos da P. angulata apresentarem uma grande variedade de substâncias, pouco é conhecido sobre a sua atividade farmacológica. Neste trabalho foi investigado a atividade antileishmania in vitro de seco-esteroides (fisalinas) purificados da P. angulata. O tratamento com as fisalinas B, F e G causou uma inibição concentração-dependente do crescimento de promastigotas de Leishmania amazonensis em cultura axênica, com valores de IC50 de 6,8, 1,4, e 9,2 μM respectivamente. A fisalina D foi menos ativa, com valores de IC50 de 30,5 μM. Foi também observada uma atividade leishmanicida em culturas de outras espécies de Leishmania (L. major, L. braziliensis e L. chagasi). Nossos resultados demonstram que as fisalinas inibem o crescimento dos promastigotas com o tratamento de espécies de Leishmania do Velho e do Novo Mundos e sugerem o potencial terapêutico destas moléculas na leishmaniose.
Unitermos: Leishmania sp., isalinas, promastigotas, seco-esteroides.
ABSTRACT: Physalis angulata L., Solanaceae, is an annual herb commonly used in popular medicine in many tropical and subtropical countries. P. angulata extracts contain a variety of substances, but little is known about their pharmacological activities. In this work we investigated the in vitro antileishmanial activity of seco-steroids (physalins) purified from P. angulata. Addition of physalins B, F, and G caused a concentration-dependent inhibition in the growth of L. amazonensis promastigotes, being the IC50 values 6.8, 1.4, and 9.2 μM, respectively. Physalin D was less active and had an IC50 value of 30.5 μM. Physalins were also active in cultures of other Leishmania species (L. major, L. braziliensis, and L. chagasi). Our results demonstrate the potent antileishmanial activity of physalins in cultures of Leishmania species of the New and Old Worlds and suggest the therapeutic potential of these seco-steroids in leishmaniasis.
Keywords:Leishmania sp., physalins, promastigotes, seco-steroids.
20(6): 945-949, Dez. 2010
Article
Received 18 Jun 2009; Accepted 21 Jun 2010; Available online 12 Nov 2010.
Effects of seco-steroids puriied from
Physalis angulata
L.,
Solanaceae, on the viability of
Leishmania
sp.
Elisalva T. Guimarães,
1Milena S. Lima,
1Luana A. Santos,
1Ivone M. Ribeiro,
2Therezinha B. C. Tomassini,
2Ricardo Ribeiro dos Santos,
1,3Washington L. C. dos Santos,
1Milena B. P. Soares
*,1,31Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Rua Waldemar Falcão 121, 40296-710 Salvador-BA,
Brazil,
2FarManguinhos, Fundação Oswaldo Cruz, Rua Sizenando Nabuco 100, 21041-050 Rio de Janeiro, RJ, Brazil,
3Centro de Biotecnologia e Terapia Celular, Hospital São Rafael, Avenida São Rafael 2152,41253-190 Salvador, BA,
Brazil.
INTRODUCTION
Despite of the advances in the understanding of the immunology and molecular biology of leishmaniasis, the drugs available for the treatment of this illness still present today many adverse effects, such as acute toxicity and rapid development of drug resistance (Bryceson, 2001). The drugs most used in the treatment of leishmaniasis are pentavalent antimonials, which
have been used for more than 50 years (Iwu et al., 1994; Carvalho et al., 2001). Some lipid-based formulations of the amphotericin B, such as AmBisome, are now
indicated in the treatment of irst-line against visceral
Rev. Bras. Farmacogn.
proven biological activity applicable to the treatment of some diseases.
Physalis angulata L., Solanaceae, is an annual herb distributed in many countries located in tropical and subtropical regions of the world. This plant is widely used in popular medicine as a treatment for a variety of diseases, and has antitumoral activity already demonstrated (Lin et al., 1992; Chiang et al., 1992). In addition, this plant has compounds with anti-T. cruzi activity (Nagafuji et al., 2004; Abe et al., 2006).
Physalin H, isophysalin B and others isolated of Physalis minima have shown leishmanicidal activity against the promastigotes of Leishmania major (Choudary et al., 2005; Choudary et al., 2007). We have investigated the activities of a group of seco-steroids isolated from
P. angulata, known as physalins, and demonstrated the immunomodulatory activity of physalins in vitro and in vivo (Soares et al., 2003; Soares et al., 2006). In this work we investigated the antileishmanial effects of physalins B (1), D (2), F (3), and G (4), in vitro against promastigotes of Leishmania sp. Our results suggest that these drugs could be candidate for treatment of leishmaniasis.
MATERIALS AND METHODS
Parasites and drugs
L. amazonensis (MHOM/BR88/BA-125 Leila
strain), L. major (MHOM/RI/-/WR-173), L. chagasi
(MHOM/BR2000/Merivaldo2), and L. braziliensis (MHOM/BR88/BA-3456) promastigotes were cultivated
in liver infusion tryptose (LIT) medium supplemented with 10% fetal bovine serum (FBS) (Cultilab, Campinas,
SP, Brazil), 5% sterile urine and 50 μg/mL gentamycin (Sigma, St. Louis, MO, USA), pH 7.2, at 26 oC until
logarithmic phase. Physalins B (1), D (2), F (3), and G (4) were obtained from plant specimens collected in
Belém do Pará, Brazil, as described before (Soares et al.,
2003).
Antileishmanial assay
Promastigotes of L. amazonensis, L. major, L. chagasi, and L. braziliensis were grown in axenic cultures (seeding 2x 106 in 5 mL) were incubated with 2,
5 or 15 μg/mL of physalins B, D, F and G. The parasites
were observed and counted using a Neubauer chamber.
Parasite growth inhibition was evaluated up to 5-7 days
of treatment.
Statistical analyses
For comparing multiple groups with matched observations Friedman test was used followed by Dunns test for comparing selected groups. The inhibitory concentrations for 50% (IC50) of Leishmania growth, at
ifth or seventh days of incubation, were calculated based in a nonlinear regression (curve it) and the statistical
analyses were made by one-way ANOVA and
Newman-Keuls multiple comparison test using Prism version 4.00 for Windows, GraphPad Software (San Diego, CA). The critical level of signiicance was established for p<0.05.
RESULTS
Physalins B, G, and F, but not D, inhibit the growth of
Leishmania spp.
To evaluate the anti-leishmania activity of physalins, promastigotes of L. amazonensis, L. major, L. braziliensis, and L. chagasi were incubated with different concentrations of the different physalins in axenic cultures. Treatment of parasites with physalin B resulted in a concentration-dependent inhibition on the proliferation of promastigotes (Figure 1). This drug reduced completely the promastigotes number since the
irst day of treatment when the concentration of 15 µg/
mL was used. In addition, physalins F and G inhibited the
growth of L. amazonensis and L. major, whereas addition
of physalin D did not signiicantly alter the growth of these two parasites even at 15 µg/mL (Figure 2). Physalin
F was more active against promastigotes than physalins B or G, and inhibited 100% the promastigotes when the smaller concentration was used. The estimation of IC50
values (Table 1) conirmed that physalin F was the most active (1.4 µM), having an activity comparable to the IC50 of amphotericin B (3.0 µM), a standard antileishmanial drug. Physalin D was the least active of the physalins tested, with an IC50 of 30.5 µM.
Figure 1. Effects of physalin B on promastigotes of Leishmania ssp. Stationary-phase promastigotes of L. amazonensis, L. major, L. chagasi, and L. braziliensis were submitted to treatment with 2, 5 and 15 mg/mL of physalin B or vehicle in axenic cultures. The number of parasites/mL was determined by daily counting using a hemacytometer. Results shown are from one representative of three independent experiments performed. *p<0.05, **p<0.01, and ***p<0.001, compared to control group.
Table 1. IC50 values for anti-L. amazonensis activity.
Drug IC50 (µM)
Physalin B 6.7
Physalin D 30.5
Physalin F 1.4
Physalin G 9.2
Amphotericin B 3.0
DISCUSSION
Previous studies have shown that physalin H,
isophysalin B, 5 beta, 6 beta-epoxyphysalin B and others isolated of Physalis minima have in vitro antileishmanial activitiy against promastigotes of L. major (Choudhary et al., 2005; Choudhary et al., 2007). In the present study we demonstrated the antileishmanial activity of physalins B, F, and G isolated from Physalis angulata in vitro in axenic cultures of different Leishmania species, including
L. amazonensis, L. braziliensis, L. chagasi (New World), and L. major (Old World).
Whereas physalins B, F, and G had potent antileishmanial activity, this was not found with physalin D, which had a high IC50 value. The lack
of immunomodulatory/anti-inlammatory activity by
physalin D, but not of physalins B, F, and G, has been described before (Soares et al., 2003; Soares et al.,
2006). In addition, Jacobo-Herrera (2006) also found that
physalins B and F, but not D, inhibited the activation of
NF-kB, an important transcription factor in inlammatory
responses, and suggested that the presence of a double bond and an epoxy ring between carbons 5 and 6 in physalins B and F, respectively, which are not present
in physalin D, are critical for the anti-inlammatory
activity.
Although some reports have demonstrated a lack of activity of physalin D, Januario (2002) reported an antimycobacterial activity of physalin D, in addition
to physalin B. Magalhães (2006) also showed that both
physalins B and D have antitumoral activity, although Chiang (1992) reported lack of activity of physalin D in human leukemia cells in vitro.
In conclusion, this study demonstrated an anti-leishmania action of physalins B, F, and G against different species, with IC50 values comparable to that of amphotericin B, a drug of reference for leishmaniasis treatment. The in vivo activity of physalin F has been demonstrated in a model of cutaneous leishmaniasis in BALB/c mice infected with L. amazonensis. These results suggest the use of physalins as an alternative drug in treatment of the cutaneous leishmaniasis.
ACKNOWLEDGEMENTS
This work was supported by FIOCRUZ/PDTIS, CNPq, Institutos do Milênio, IMSEAR, MCT, FINEP,
RENORBIO, and BIOINOVA.
REFERENCES
Abe F, Nagafuji S, Okawa M, Kinjo J 2006. Trypanocidal constituents in plants. Minor withanolides from the aerial parts of Physalis angulata. Chem Pharm Bull 54: 1226-1128.
Bryceson A 2001. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 6: 928-934.
Carvalho PB, Ferreira EI 2001. Leishmaniasis phytotherapy. Nature’s leadership against an ancient disease. Fitoterapia 72: 599-618.
Chiang HC, Jaw SM, Chen CF, Kan WS 1992. Antitumor agent, physalin F from Physalis angulata L. Anticancer Res 12: 837-843.
Choudhary MI, Yousaf S, Ahmed S, Yasmeen K, Atta-ur-Rahman 2005. Antileishmanial physalins from Physalis minima. Chem Biodivers 2: 1164-1173.
Choudhary MI, Yousaf S, Ahmed S, Yasmeen K, Atta-ur-Rahman 2007. New leishmanicidal physalins from Physalis minima. Nat Prod Rev 21: 877-883.
Iwu M, Jackson JE, Schuster BG 1994. Medicinal plants in the ight against leishmaniasis. Parasitol Today 10: 65-68. Jacobo-Herrera NJ, Bremner P, Marquez N, Gupta MP,
Gibbons S, Muñoz E, Heinrich M 2006. Physalins from Witheringia solanacea as modulators of the NF-kappaB cascade. J Nat Prod 69: 328-331.
Januário AH, Filho ER, Pietro RC, Kashima S, Sato DN, França SC 2002. Antimycobacterial physalins from Physalis angulata L. (Solanaceae). Phytother Res16: 445-448. Larabi M, Yardley V, Loiseau PM, Appel M, Legrand P, Gulik
A, Bories C, Croft SL, Barratt G 2003. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 47: 3774-3779.
Lin YS, Chiang HC, Kan WS, Hone E, Shih SJ, Won MH 1992. Immunomodulatory activity of various fractions derived from Physalis angulata L. extract. Am J Chin Med 20: 233-243.
Magalhães HI, Veras ML, Torres MR, Alves AP, Pessoa OD, Silveira ER, Costa-Lotufo LV, Moraes MO, Pessoa C 2006. In-vitro and in-vivo antitumour activity of physalins B and D from Physalis angulata. J Pharm Pharmacol 58: 235-241.
Nagafuji S, Okabe H, Akahane H, Abe F 2004. Trypanocidal constituents in plants 4. Withanolides from the aerial parts of Physalis angulata. Biol Pharm Bull 27: 193-197.
activation and lipopolysaccaride-induced death by seco-steroids puriied from Physalis angulata L. Eur J Pharmacol 459: 107-112.
